Discontinuation of Direct Oral Anticoagulants in Response to Attorney Advertisements: Data From the FDA Adverse Event Reporting System

Abstract

Get full access to this article

View all access options for this article.

References

Koski

Chamberlain

Rosoff

et al. Patient perception of transvaginal mesh and the media. Urology. 2014;84:575-582. doi:10.1016/j.urology.2014.03.051

Burton

Peacock

WF.

A Medwatch review of reported events in patients who discontinued rivaroxaban (XARELTO) therapy in response to legal advertising. HeartRhythm Case Rep. 2016;2:248-249. doi:10.1016/j.hrcr.2016.02.001

Tippett

Chen

BK.

Association of Attorney Advertising and FDA action with prescription claims: a time series segmented regression analysis. Drug Saf. 2015;38:1169-1178. doi:10.1007/s40264-015-0340-6

American Medical Association. Attorney ads on drug side effects H-105.985. https://policysearch.ama-assn.org/policyfinder/detail/Attorney%20Ads%20on%20Drug%20Side%20Effects%20H-105.985?uri=%2FAMADoc%2FHOD-105.985.xml. Accessed July 22, 2018.

Tippett

Medical advice from lawyers: a content analysis of advertising for drug injury lawsuits. Am J Law Med. 2015;41:7-48.

Patel

Hellkamp

Lokhnygina

et al. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (rivaroxaban once-daily, oral, direct factor Xa inhibition compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in atrial fibrillation). J Am Coll Cardiol. 2013;61:651-658. doi:10.1016/j.jacc.2012.09.057